### 1 Single-cell genomics improves the discovery of risk variants and genes of cardiac traits

- Alan Selewa<sup>1\*</sup>, Kaixuan Luo<sup>2\*</sup>, Michael Wasney<sup>3+</sup>, Linsin Smith<sup>4+</sup>, Chenwei Tang<sup>5</sup>, Heather
  Eckart<sup>3</sup>, Ivan Moskowitz<sup>2,6</sup>, Anindita Basu<sup>3</sup>, Xin He<sup>2#</sup>, Sebastian Pott<sup>3#</sup>
- 5
- 6 <sup>1</sup>Biophysical Sciences Graduate Program,
- 7 <sup>2</sup>Department of Human Genetics,
- 8 <sup>3</sup>Section of Genetic Medicine, Department of Medicine,
- 9 <sup>4</sup>Committee on Genetics, Genomics and Systems Biology,
- 10 <sup>5</sup>The College,
- 11 <sup>6</sup>Department of Pediatrics,
- 12 The University of Chicago, Chicago, IL 60637, USA;
- 13 \*, +, # These authors contributed equally.
- 14

15 Correspondence: obasu@uchicago.edu, xinhe@uchicago.edu, spott@uchicago

16

# 17 Abstract

18 Genome-wide association studies (GWAS) have linked hundreds of loci to cardiac diseases. 19 However, in most loci the causal variants and their target genes remain unknown. We developed 20 a combined experimental and analytical approach that integrates single cell epigenomics with 21 GWAS to prioritize risk variants and genes. We profiled accessible chromatin in single cells 22 obtained from human hearts and leveraged the data to study genetics of Atrial Fibrillation (AF), 23 the most common cardiac arrhythmia. Enrichment analysis of AF risk variants using cell-type-24 resolved open chromatin regions (OCRs) implicated cardiomyocytes as the main mediator of AF 25 risk. We then performed statistical fine-mapping, leveraging the information in OCRs, and 26 identified putative causal variants in 122 AF-associated loci. Taking advantage of the fine-27 mapping results, our novel statistical procedure for gene discovery prioritized 45 high-confidence 28 risk genes, highlighting transcription factors and signal transduction pathways important for heart 29 development. We further leveraged our single-cell data to study genetics of gene expression. An 30 unexpected finding from earlier studies is that expression QTLs (eQTLs) are often shared across 31 tissues even though most regulatory elements are cell-type specific. We found that this sharing is 32 largely driven by the limited power of eQTL studies using bulk tissues to detect cell-type-specific 33 regulatory variants. This finding points to an important limitation of using eQTLs to interpret 34 GWAS of complex traits. In summary, our analysis provides a comprehensive map of AF risk 35 variants and genes, and a general framework to integrate single-cell genomics with genetic studies 36 of complex traits.

#### 38 Introduction

Cardiac diseases are a leading cause of mortality across the world<sup>1,2</sup>. GWAS of cardiac traits have 39 40 uncovered a large number of associations, such as >100 loci linked to atrial fibrillation  $(AF)^{3-7}$ . 41 However, in most loci the disease-driving causal variants and risk genes remain unknown due to 42 several common challenges. Most trait-associated variants are located in non-coding regions with possible regulatory effects<sup>8</sup> and studies have highlighted enrichment of risk variants in cis-43 44 regulatory elements (CREs) in trait-related cell and tissue types<sup>8-10</sup>. Existing disease-related 45 regulatory and epigenomic datasets, however, were often collected from bulk tissue samples that represent complex mixtures of cell types<sup>11,12</sup>. A lack of cell type-resolved epigenomic data thus 46 47 limits our ability to interpret regulatory effects of variants. Even with comprehensive epigenomic 48 maps, extensive linkage disequilibrium (LD) in the human genome hinders identification of causal 49 variants in trait-associated loci. Additionally, non-coding variants are not easily associated with 50 their target genes because of pervasive long-range gene regulation. Together, these challenges 51 make it difficult to translate GWAS associations into molecular mechanisms.

52 To address these challenges in the context of heart diseases, we developed an integrated 53 framework that unifies advances in single cell epigenomics, computational fine-mapping and a 54 novel procedure for risk gene discovery. Specifically, we performed single-cell chromatin 55 accessibility profiling to map CREs across major cell types in the heart. Our statistical fine-56 mapping method utilizes the CRE maps to infer disease-relevant cell types and takes advantage of 57 such information to identify putative causal variants. Our novel gene-mapping approach then 58 aggregates information of all fine-mapped SNPs to predict the risk genes, considering multiple 59 sources of information such as distance and chromatin loops between enhancers and promoters. Application of this framework to AF revealed a number of putative risk variants and genes, 60 61 highlighting biological processes important to the genetics of AF.

Motivated by our success in studying genetics of heart diseases, we took advantage of our singlecell genomics data to study genetics of gene expression, i.e., expression QTLs (eQTLs). By linking genetic variants with gene expression, eQTLs help annotate the regulatory effects of variants and have been used as key resources for interpreting GWAS findings<sup>13,14</sup>. An unexpected finding from eQTL studies is that eQTLs from diverse tissues show a high degree of sharing<sup>15,16</sup>, despite cell type specificity of most CREs<sup>17</sup>. This finding is important, as it suggests the possibility that current eQTL studies may provide limited information for studying diseases, which are generally specific

to certain tissues or organs. Indeed, it was estimated that eQTLs from bulk gene expression may explain only 10-20% of disease heritability<sup>18</sup>. It has been difficult to resolve the puzzle of eQTL tissue sharing, largely due to the lack of cell-type information for identified eQTLs from bulk tissue samples. Taking advantage of our data, we were able to assign cell types to many heart eQTLs. Our analysis suggests two key factors for explaining high tissue-sharing of eQTLs, the sharing of cell types across tissues and the low sensitivity of bulk eQTL studies in detecting celltype specific regulatory effects.

- 76
- 77 Results

78 **Overview of the experimental and computational approach.** Our approach combines single-79 cell genomics with novel computational procedures to study genetics of cardiac traits (Fig. 1). Using single nucleus RNA-sequencing<sup>19-21</sup> (snRNA-seq) and single cell ATAC-seq (scATAC-80 81 seq)<sup>22,23</sup>, we obtained transcriptome and open chromatin regions (OCRs) across all major cell types 82 in the adult human heart (Fig. 1, step 1). These OCR profiles allow us to discover cell types 83 enriched with the genetic risks of traits of interest. To identify specific causal variants in trait-84 associated loci, we performed Bayesian statistical fine-mapping, a common strategy that uses GWAS statistics as well as LD patterns to infer likely causal variants driving association signals<sup>24</sup>. 85 86 Compared to standard fine-mapping, our method assigns prior probabilities to favor variants 87 located in OCRs of enriched cell types (Fig. 1, step 2). The use of functionally informed prior has been shown to improve the accuracy of fine-mapping<sup>9,25,26</sup>. We believe this is particularly 88 89 advantageous with single-cell data. Indeed, compared to OCRs from bulk tissues which include a 90 mixture of all cell types, the OCRs in disease-relevant cell types would be particularly enriched 91 with genetic signals. After fine-mapping, the candidate SNPs and their associated cell-type 92 information allow us to assign the cell type(s) through which the causal variants are likely to act 93 across disease-associated loci.

Finally, we developed a procedure to infer causal genes at each locus (Fig. 1, step 3), addressing some common challenges. In "gene association tests", researchers test if the set of SNPs near a gene collectively show disease association<sup>27,28</sup>. These types of methods, however, cannot distinguish between multiple genes close to disease-associated variants. Alternatively, researchers may perform fine-mapping first, then link the high-confidence SNPs to target genes using additional information. However, fine-mapping alone rarely leads to a single, or even a few, high

confidence SNPs at associated loci<sup>29</sup>, therefore this approach also has limited utility. In contrast, 100 101 our procedure is directly informed by variant fine-mapping, but instead of considering only high-102 confidence SNPs, it aggregates information of all fine-mapped ones in a locus. To see its benefit, 103 suppose fine-mapping in a locus implicates 10 putative causal variants without any single one 104 reaching high confidence; however, if all 10 SNPs likely target the same gene, we still achieve 105 high-confidence at the gene level. To implement this idea, our procedure partitions the evidence 106 of a SNP being causal variant into nearby genes, with its likely target genes receiving larger 107 evidence. The information is then aggregated across all SNPs to produce gene level evidence. The details are described below (Fig. 5a) and in Methods. 108

109

# 110 Single-cell transcriptome and chromatin accessibility profiling reveals multiple cell types in

the human heart. We performed snRNA-seq and scATAC-seq using the Chromium platform (10x Genomics) (Fig. 1, step 1). The heart samples were obtained from the left and right ventricles (LV and RV), the interventricular septum, and the apex of three adult male donors (Supplementary Table 1). After quality control, we retained data of 49,359 cells in snRNA-seq and 26,714 cells in scATAC-seq, respectively (Extended Data Fig. 1 and 2).

116 We characterized cell populations with clustering analysis in both snRNA-seq and scATACseq datasets. From snRNA-seq<sup>30</sup>, we identified eight major cell types based on marker genes and 117 comparison to published single-cell heart atlas data<sup>20</sup> (Fig. 2a, left), with  $\sim 70\%$  of cells from 118 119 cardiomyocytes (CMs), fibroblasts, and endothelial cells. Clustering based on scATAC-seq data<sup>31</sup> 120 revealed similar cell populations (Fig. 2a, right). To match the clusters identified by both 121 technologies, we computationally transferred cluster labels from snRNA-seq onto scATAC-seq 122 clusters<sup>30</sup> (Methods) and unambiguously identified matching cell types (Extended Data Fig. 3a, b). 123 Indeed, expression and chromatin accessibility near marker genes showed high cell-type 124 specificity (Fig. 2b, c). Across the eight clusters, gene scores inferred from scATAC-seq, a metric that summarizes the chromatin accessibility near a gene<sup>31</sup> (Methods), were highly correlated with 125 126 transcript levels in the matched clusters (Extended Data Fig. 3c). These results supported the cell-127 type assignments in both modalities.

129 Analysis of scATAC-seq data identifies cell-type-specific regulatory elements and their 130 regulators. We pooled cells of the same cell type and identified OCRs separately in each cell type.

131 Combining samples of the same cell type (Extended Data Fig. 4a, b), we detected 45,000-150,000 132 OCRs per cell type (Extended Data Fig. 4c) yielding a union set of 352,904 OCRs. K-means 133 clustering of these regions based on their accessibility suggested that most OCRs are active in 134 specific cell types (Fig. 3a). Using differential accessibility (DA) analysis, we identified 173,782 (49%) OCRs with cell-type-specific accessibility (Methods). We divided the remaining 179,122 135 136 (51%) OCRs into three categories based on their detection across cell types: shared in 2-3 cell 137 types, shared in >=4 cell types (denoted as Shared 2-3 and Shared 4), and remaining ones, denoted 138 as "non-DA OCRs", which mostly comprise peaks with low read counts (Methods). In agreement 139 with previous observations, shared OCRs were enriched in promoter regions<sup>32</sup> (Fig. 3b, c).

140 We compared our OCRs to regulatory regions identified in bulk samples from multiple tissues in ENCODE<sup>12</sup>. As expected, a large fraction of OCRs from major heart cell types (e.g., CMs, 141 142 endothelial, fibroblasts) overlapped with DNase Hypersensitive sites (DHS) from the ventricles 143 (Fig. 3d, top). In contrast, smaller proportions of OCRs from rare cell types (e.g., myeloid) 144 overlapped with bulk DHS, suggesting higher sensitivity of detecting regulatory elements in rare 145 cell types by scATAC-seq (Fig. 3d, top, Extended Data Fig. 4d). Additionally, 60-80% of OCRs 146 from major cell types overlapped with H3K27ac regions from LV and RV, suggesting enhancer 147 activity (Fig. 3d, bottom). Together, these results showed that scATAC-seq identified cell-type 148 specific regulatory elements.

Chromatin accessibility is largely controlled by lineage-specific transcription factors (TFs)<sup>33</sup>. 149 150 To identify these TFs, we assessed the enrichment of TF motifs in OCRs specific to each cell type 151 and identified 260 significantly enriched motifs (Methods). Because TFs of the same family may 152 share similar motifs, we performed additional analysis to infer the exact TFs driving the 153 enrichment, assuming that for these TFs, their motif enrichment should correlate with gene 154 expression across cells. To test this, we correlated motif accessibility scores of TFs calculated by chromVar<sup>34</sup> with their accessibility-derived gene scores, a proxy of gene expression<sup>31</sup> (Methods). 155 156 This analysis yielded 76 TFs with enriched motifs and correlation > 0.5 (Fig. 3e, Supplementary 157 Table 2). Many of these TFs are cell type-specific (Fig. 3e) and include known CM regulators, 158 such as TBX5, GATA4, and MEF2A<sup>35</sup> (Fig. 3f). These results provided a compendium of putative 159 transcriptional regulators across major cell types in the human heart. 160

#### 161 Open chromatin regions in CMs are enriched with risk variants of heart diseases and inform

162 statistical fine-mapping. Using our cell-type-resolved OCRs, we assessed the contribution of 163 different cell types to genetics of heart-related traits<sup>36</sup>. Risk variants from GWAS of two cardiac 164 traits, AF and PR interval, were almost exclusively enriched (>10-fold) in OCRs from CMs (Fig. 165 4a). In contrast, variants of cardiovascular traits, CAD and blood pressure, were enriched across 166 multiple cell types (Fig. 4a). As control, non-cardiovascular traits showed little or no enrichment 167 in heart cell types (Fig. 4a). These results suggested distinct cell type origins of different heart-168 related traits, highlighting CMs as the main cell type underlying AF and PR interval.

This observation motivated us to statistically fine-map causal variants in 122 approximately 169 independent AF-associated loci<sup>37</sup>. Our procedure favors putatively functional variants in protein-170 coding regions, conserved sequences, and OCRs in CMs (Extended Data Fig. 5a, Methods)<sup>38</sup>. 171 172 Compared to fine-mapping that treats all variants equally (uniform prior), this procedure increased 173 the number of high-confidence risk variants. In total, we identified 54 variants whose probabilities 174 of being causal variants, denoted as Posterior Inclusion Probabilities (PIP), are 0.5 or higher, 175 compared with 39 at PIP  $\geq 0.5$  under the uniform prior (Fig. 4bc, Supplementary Table 3). Across 176 122 loci, our procedure narrowed down putative causal variants to 5 or fewer SNPs in 48 loci (Fig. 177 4d).

The fine-mapping results inform how the risk variants are partitioned into various functional categories, such as exons and OCRs in different cell types. The sum of PIPs of all SNPs assigned to a category can be interpreted as the expected number of causal variants in that category. We found that >40% of causal signals are from OCRs and 25% of signals from CM-specific OCRs, highlighting the key role of CMs in AF (Fig. 4e). As expected, exons and UTRs explain only 4% of causal signals.

184 The same PIP summation approach can also be applied to each locus, with the PIP sum of a 185 functional category, e.g., OCRs or exons, now interpreted as the probability that the causal variant 186 in that locus falls into that category. Using this approach, we estimate that at nearly half of all loci, 187 causal variants have >50% probability to localize to OCRs (Fig. 4f). Further partitioning of OCRs 188 into cell-type-level categories (Fig. 3b), we identified 31 loci where the causal signals almost 189 entirely (>90%) come from CM-OCRs (Fig. 4g). Interestingly, in three loci, the most likely cell 190 types are fibroblast or immune cells, respectively, based on OCR annotations (Fig. 4g, 191 Supplementary Table 4). For example, at one locus (chr17:36809344-38877404), lymphoid OCRs

explain 56% causal signal and the most likely target gene is *IKZF3* (see our gene mapping results below), a TF involved in the regulation of lymphocyte development<sup>39</sup>. In another locus (chr17:7317398-8306425), myeloid OCRs explain 53% causal signal, with the most likely gene being *TNFSF13*, another gene with immune functions<sup>40</sup>. Together these results highlighted that our approach can identify cell type contexts of individual loci, including the cell types missed by enrichment analysis.

198

199 Fine-mapped variants are supported by regulatory annotations and experimental validation. 200 We characterized the regulatory functions of 54 specific variants at PIP  $\geq 0.5$ . The majority (31/54) were located in CM-OCRs (Fig. 4h, Supplementary Table 3). 57% (31/54) of all variants 201 202 and 87% (27/31) of variants in CM-OCRs overlapped H3K27ac marks in the heart, suggesting enhancer activities (Fig. 4h). 37% of variants (20/54) overlapped with fetal DHS<sup>12</sup>, suggesting that 203 204 these variants may act across fetal and adult stages (Fig. 4h). Additionally, 24% of variants were 205 linked to promoters through chromatin loops in Promoter-capture HiC (PC-HiC) from iPSC derived CMs<sup>41</sup> (Fig. 4h). Using mouse ChIP-seq datasets of three key cardiac TFs (GATA4, TBX5, 206 207 NKX2-5)<sup>35</sup>, we found that five candidate variants are located in human orthologous regions of TF 208 binding sites, representing 7-fold enrichment over expectation by chance (Extended Data Fig. 5b). 209 We also found that 22% (12/54) SNPs alter binding motifs (Fig. 4h) of one of the 76 TFs we 210 identified as likely transcriptional regulators in heart cell types (Fig. 3e). Together, these results 211 supported regulatory functions of many fine-mapped variants.

212 We experimentally tested six non-exonic variants with PIP > 0.95 that were located inside CM-213 OCRs and overlapped with putative enhancers marked by H3K27ac or H3K4me1/3 (Fig. 4i, 214 Supplementary Table 5). Four out of six variant-containing OCRs induced reporter gene 215 expression in mouse HL-1 cells<sup>42,43</sup> (Extended Data Fig. 6a, Methods), but not in a fibroblast line 216 (3T3), suggesting cell-type-specific activity of the four OCRs (Extended Data Fig. 6b). Three out 217 of these four variants showed allelic changes of reporter activities in HL-1 cells, for at least one 218 alternative allele (Fig. 4i). The most striking effect was observed for rs7172038. Two alternative 219 alleles of this SNP (A and G) strongly reduced activation. The enhancer containing this SNP 220 interacts with the promoter of HCN4 located about 5 kb away, according to Activity-by-Contact (ABC) score<sup>44</sup> (Supplementary Table 3). HCN4 is a well-known AF risk gene and is 221 physiologically implicated in cardiac rhythm control<sup>45</sup>. Consistent with these results, deletion of a 222

syntenic 20 kb region in mice containing this enhancer significantly reduced the expression of *HCN4<sup>46</sup>*. Notably, in two out of three SNPs with allelic effects, the use of functional information in fine-mapping significantly boosted their PIPs to  $\geq 0.95$  (PIP = 0.36 for rs7172038 and 0.39 for rs1152591 under the uniform prior). These experimental results supported regulatory functions of our high confidence variants.

In principle, we expect regulatory variants to affect transcript levels of target genes. Using GTEx eQTL data from the left ventricle (LV), we found that only 29% (16/54) variants are eQTLs (Supplementary Table 6). And only in three cases, the eQTLs showed plausible evidence of colocalization (PP4 > 0.2 using coloc<sup>47</sup>) with the AF risk (Supplementary Table 6). The small overlap of fine-mapped variants with heart eQTLs suggests a limitation of bulk eQTL data to identify regulatory variants, an issue we will address in more detail below.

234

235 A novel computational procedure utilizes fine-mapping results to identify AF risk genes. 236 Despite our fine-mapping efforts, there remained considerable uncertainty of causal variants in 237 most loci (Fig. 4d). Even if the causal variants are known, assigning target genes can be difficult 238 due to long-range regulation of enhancers<sup>48</sup>. We developed a novel procedure, called Mapgen, to 239 address these problems (Fig. 5a): (1) For every putative causal SNP, we assign a weight to each 240 nearby gene, considering multiple ways a SNP may affect a gene. The weight of a gene can be 241 viewed as the probability with which a particular SNP affects that gene. For a SNP in an exon or 242 in a regulatory region linked to a particular gene, we assign a weight of 1 to that gene. When a 243 SNP cannot be linked to any gene in these ways, its target genes are assigned using a distance 244 weighted function (Fig. 5a, Methods). (2) The PIP of each SNP is then distributed among all 245 potential target genes according to the weights of these genes. The "fractional PIP" a gene receives 246 from a SNP can be viewed as the support the SNP provides to that gene. (3) For each gene, we 247 then sum over the fractional PIPs it receives from all candidate SNPs in the region. The resulting 248 "gene PIP" approximates the probability of a gene being causal (Methods). Similar to variant-level 249 fine-mapping, we also define a "credible gene set", the set of genes that capture the causal signal 250 at a locus with high probability (Methods).

We identified 45 genes with gene PIP  $\geq 0.8$ , and 88 with gene PIP  $\geq 0.5$  (Fig. 5b, Supplementary Table 7, and Table 1 for top prioritized genes). At each locus, we obtained credible gene sets that captured at least 80% of the causal signal. These credible gene sets contained a single

gene in 41 out of 122 blocks, and two genes in 32 blocks (Fig. 5c, Supplementary Table 8). The genes at PIP >= 0.8 included many known AF risk genes such as TFs involved in cardiac development and atrial rhythm control (e.g.  $TBX5^{49}$  and  $PITX2^{50}$ ), ion channels (e.g.  $KCND2^{51}$  and  $KCNN3^{52}$ ), and genes involved in muscle contraction (e.g. TTN).

We note that a key benefit of Mapgen is that even in the absence of high-confidence causal variants, it may still identify putative risk genes. In 20 out of 45 genes at PIP >= 0.8, the SNP level PIPs were diffused, i.e., no single SNP reached PIP >= 0.5 (Supplementary Table 7). As an example, *CAMK2D*, an ion channel gene implicated in AF<sup>53</sup>, was supported by eight SNPs (highest PIP = 0.43), all likely targeting *CAMK2D*. This led to a gene level PIP = 0.996 (Extended Data Fig. 7a, Supplementary Table 3). This observation thus highlighted the advantage of aggregating information from all putative causal variants.

We compared the Mapgen results with those of three common approaches for nominating target genes: closest proximity to risk SNPs, chromatin conformation that links variant-containing enhancers to target promoters, and eQTL analysis.

268 We first assessed the distance between supporting SNPs and their predicted target genes. Among 269 the 45 genes at PIP  $\geq 0.8$ , six (15%) were not the nearest genes to the top GWAS SNPs: *ETV1*, TAB2<sup>54</sup>, FGF9, PLN<sup>55,56</sup>, CALU<sup>57</sup> and DBX1. All except DBX1 have previously described impact 270 on cardiovascular physiology or rhythm (Supplementary Table 9). For example, ETV1<sup>58,59</sup>, a TF 271 important in heart development<sup>60</sup> has been recently implicated in atrial remodeling and AF<sup>59</sup>. 272 273 FGF9 is supported by rs9506925 (SNP PIP 0.76) which is linked, via PC-HiC, to the FGF9 274 promoter 1 Mb away (Fig. 5d). FGF signaling and specifically FGF9 have been implicated in muscle/heart development and diseases<sup>61,62</sup>. Another important difference between Mapgen and 275 276 the common practice of choosing the nearest genes is that the latter always chooses a single 277 candidate in a locus but does not quantify the uncertainty. For instance, rs1152591 had a PIP of 278 0.96, yet it contacts the promoters of four genes in PC-HiC. Two of these genes appear plausible from external evidence (SYNE263,64 and AKAP565,66), but neither is nearest to the SNP (Extended 279 280 Data Fig. 7b, Supplementary Table 3). Our gene PIPs reflect this uncertainty: all four genes had 281 gene PIP  $\sim 0.25$ . Together, these results show the limitations of assigning nearest genes as targets 282 and suggest that a probabilistic approach incorporating multiple sources of information is 283 preferable.

284 We also considered the use of chromatin conformation in resolving target genes of high PIP 285 SNPs. We found that while chromatin looping data were useful, as shown in the FGF9 example 286 above, using such information alone may miss many potential risk genes. Among 54 SNPs at  $PIP \ge 0.5$ , only three showed chromatin interactions with promoters based on ABC scores<sup>67</sup>, and 287 288 14 if we included both ABC and PC-HiC data. Additionally, it is common to observe multiple 289 chromatin loops at a single SNP. Among the 14 SNPs with chromatin interactions, 64% (9/14) 290 contact more than one promoter (Supplementary Table 3), highlighting the uncertainty of target 291 genes from chromatin looping data.

Use of expression QTLs is another common strategy for linking SNPs to genes. However, as reported above, few fine-mapped variants colocalized with eQTLs. Even if a GWAS SNP is also an eQTL, it may not identify the correct target gene. For example, in the *TTN* locus, the top SNP (rs3731746) is an eQTL of *FKBP7*, but the true risk gene is very likely *TTN*<sup>68,69</sup>.

Altogether, these results demonstrated the improved ability of Mapgen to nominate plausiblecandidate genes compared to alternative approaches linking SNPs to genes.

298

299 Putative AF risk genes are supported by multiple lines of evidence. We evaluated our candidate 300 genes using multiple sources of data. Consistent with enrichment of AF variants in CM-OCRs, 301 candidate genes (PIP  $\geq 0.8$ ) tended to have higher expression in CMs, compared with other genes 302 in the AF-associated loci (Fig. 5e). Additionally, high PIP genes were enriched in AF-related 303 Mendelian disorders (Supplementary Table 10) (Fig. 5f). We also compared our genes with those 304 prioritized by earlier work that used additional functional data such as AF-related gene ontology and heart gene expression<sup>5,70</sup>. While such functional data was not used in our analysis, the genes 305 306 at PIP  $\geq 0.8$  scored on average substantially higher in two earlier studies than low PIP genes 307 (Extended Data Fig. 8), and 32 of them (71%) were supported by at least one study (Supplementary 308 Table 7).

We next assessed the functions of candidate genes using Gene Ontology (GO) and gene networks<sup>71</sup>. GO analysis showed enrichment of Biological Processes related to heart development and cardiac function, and of Molecular Functions such as ion channels, hormone binding and protein tyrosine kinase (Fig. 5g, Supplementary Table 11). For network analysis, we used the STRING gene network built with genes at a relaxed PIP threshold of 0.5 (88 genes) to increase the number of interactions. This analysis highlighted some well-known processes in AF, such as ion

315 channels, and structure components of heart muscle (Fig. 5h). A prominent subnetwork consisted 316 of key TFs, including GATA4, TBX5, NKX2-5 and HAND2, implicated previously in AF genetics 317 and/or heart development<sup>49,72-74</sup> (Fig. 5h). Two other TFs in the network, *PITX2* and *ZFHX3*, are also well-known AF genes<sup>49</sup>. Combined with the fact that putative causal variants were enriched 318 319 in binding sites of TBX5, NKX2-5 and GATA4 (Fig. 4h, Extended Data Fig. 5b), these results 320 suggested that perturbation of transcriptional regulatory networks consisting of TFs and their 321 targets, plays a critical role in the genetics of AF. Additionally, the interaction network highlighted 322 signal transduction pathways, including MAPK signaling and Ephrin signaling (Fig. 5h). Both 323 processes are important in heart development<sup>75–78</sup>. Indeed, 19 out of 88 genes at PIP  $\geq 0.5$  were 324 annotated by the GO term "regulation of intracellular signal transduction" (FDR < 0.02) 325 (Supplementary Table 12).

Finally, we found additional literature support for the candidate genes. 37 out of 45 (82%) genes at PIP  $\geq 0.8$  have reported roles in cardiac processes and/or diseases from literature (Supplementary Table 9). The subset of genes at PIP  $\geq 0.95$  with literature support, as well as their supporting SNPs, were shown in Table 1. The majority of these genes have not been established as AF risk genes through functional studies, representing novel yet biologically plausible risk genes.

332

333 Cell-type-specific epigenomes reveal insights to extensive tissue-sharing of bulk eQTLs. 334 While a large fraction of fine-mapped AF SNPs fell inside CM-specific OCRs (Fig. 4e), most of 335 them did not colocalize with heart eQTLs (Supplementary Table 6). This observation is consistent 336 with previous findings that only a small proportion of GWAS variants or heritability are explained by eQTLs<sup>18,79</sup>. We hypothesized that bulk eQTL studies, which are conducted on bulk tissues 337 338 consisting of multiple cell types, may miss the gene regulatory effects of causative variants because 339 of limited power to detect eQTLs with effects restricted to certain cell types. This hypothesis may 340 also help explain the puzzling observation that despite the cell-type-specific nature of regulatory elements, discovered cis-eQTLs are highly shared across tissues<sup>16</sup>. Cell-type-resolved chromatin 341 342 accessibility and transcriptome data allowed us to infer cell-type origins of bulk eQTLs and 343 provided an opportunity to investigate eQTL tissue-sharing patterns.

We focused our analysis on 1,216 heart (LV) eQTLs from GTEx where the causal variants have been fine-mapped to single variants with high confidence (PIP  $\geq 0.8$ ) by the GTEx consortium

(Supplementary Table 13). We divided these eQTLs into disjoint classes based on eQTL locations,
including exons, UTRs, introns, OCRs in specific cell types, and OCRs shared with varying
numbers of cell types. These categories suggested possible cell-type origins of eQTLs and allowed
us to compare tissue sharing patterns of different categories, e.g., eQTLs in cell-type-specific
OCRs vs. those in shared OCRs across cell types (see Methods).

351 We first confirmed that the majority of eQTLs were highly shared, i.e., found in >30 tissues in 352 GTEx (Fig. 6a). This high degree of sharing, however, masked heterogeneity across different 353 categories. While eQTLs falling into OCRs shared in multiple cell types were extensively shared 354 across tissues (Fig. 6b), eQTLs in cell-type-specific OCRs showed variable levels of sharing. 355 Fibroblast-eQTLs (eQTLs in fibroblast-specific OCRs) and myeloid-eQTLs were highly shared (median 25 and 38 tissues, respectively), but most CM-eQTLs were found in <10 tissues (Fig. 6b). 356 357 We hypothesized that this variability reflected different degrees of cell type sharing between the 358 heart and other tissues, with fibroblasts and myeloid cells shared in more tissues and CMs shared 359 in fewer. To test this, we compared heart eQTLs with those from the brain and whole blood. As 360 expected, heart eQTLs from immune cell OCRs had the highest sharing with whole blood, while 361 eQTLs of all heart cell types have low sharing with the brain (Fig. 6c). Together, our results 362 highlighted considerable variability of tissue sharing patterns of heart eQTLs, depending on their 363 likely cell-type origins.

364 This finding appeared contradictory to the overall high level of tissue sharing of eOTLs. To 365 understand to understand the basis for this observation, we assessed the proportions of heart eQTLs 366 in functional categories, focusing on eQTLs in OCRs, whose cell type origins could be inferred. 367 Unexpectedly, a large proportion of those eQTLs were from OCRs shared in multiple cell types 368 (Fig. 6d), even though more than half of all OCRs were cell-type-specific (Fig. 3a). To better 369 understand these results, we compared the proportions of eQTLs in each category with the 370 proportions of matched random control SNPs (Methods). While eQTLs in OCRs from single cell 371 types showed 2-9 fold enrichment, those shared with 4 or more cell types showed 26-fold 372 enrichment (Fig. 6d). Indeed, the enrichment is highly correlated with the number of cell types in 373 which an OCR is detected (Fig. 6e). We thus concluded that discovered eQTLs are biased towards 374 those with broad effects across multiple cell types, explaining the overall high tissue-sharing across 375 eQTLs.

376 We reasoned that this bias towards eQTLs with shared effects, or equivalently, the depletion of 377 cell-type-specific eQTLs, can be explained by the nature of bulk eQTL studies. When the effect 378 of an eQTL on a gene is limited to a single cell type, but the gene is expressed in other cell types, 379 the effect of the variant on the bulk gene expression would be diluted, leading to lower power of 380 detecting this eQTL. This argument was supported by the observation that gene expression was 381 less cell-type-specific than accessibility of regulatory elements. In heart eQTLs localized to CM-382 specific OCRs, the expression of corresponding genes in CMs were only modestly higher than 383 their expression in other cell types (Extended Data Fig. 9a).

384 We performed simulations to investigate the power loss in detecting cell-type-specific eOTLs. 385 We considered a variant that is an eQTL of a gene in one cell type ("focal" cells). Mathematical 386 analysis showed that the power of detecting association of this variant with bulk expression 387 depends on effect sizes of the variant in all cell types, the cell type proportions, and the variance 388 as well as correlations of gene expression across cell types (Supplementary Notes). Under 389 simplified assumptions about the variance and correlation of expressions across cell types, and a 390 cell type mix similar to our heart data, we estimated that, when the focal cells are 30% of the 391 sample, the power of detecting the eQTL, at sample size 500 and p-value < 1e-3, is about 26-88% 392 (depending on effect size) of the maximum power; and when focal cell proportion is 20%, reduces 393 to only 8-40% (Extended Data Fig. 9b, Supplementary Notes).

In conclusion, our empirical study and power analysis together showed that sharing of cell types across tissues, and the under-detection of cell-type-specific regulatory variants are two factors explaining high level of tissue-sharing of bulk eQTLs. The latter factor may also explain the finding that cis-eQTLs from bulk tissues only mediate 10-20% of disease heritability. Together our finding points out limitations of current eQTL studies and highlights the need of other strategies such as single-cell eQTL mapping<sup>81</sup>.

400

#### 401 **Discussion**

While GWAS have been successful in a range of complex traits, the causal variants, their target genes, and their mechanisms in disease-related cell types have been elucidated in few cases<sup>48</sup>. In this work, we established a cell-type-resolved atlas of chromatin accessibility and transcription of the human heart to study the genetics of heart-related traits, focusing on  $AF^{3-5}$ . We statistically fine-mapped AF-associated loci, and experimentally validated some of the candidate variants.

407 Using a novel computational procedure, we identified 45 high confidence genes, implicating key 408 biological processes, in particular TFs and signaling pathways important for heart development. 409 Motivated by our observation that the putative AF variants often were not colocalized with eQTLs, 410 we investigated how heart eQTLs are shared across tissue types. Our analysis suggests that eQTLs 411 with cell-type-specific effects are under-detected and that this is likely a factor explaining both 412 high tissue-sharing of eQTLs and the lack of eQTLs in GWAS variants.

413 Single-cell epigenomics has been used to aid the genetic studies of several common diseases, 414 including  $AF^{82-85}$ . These studies, however, often aimed to assess the key cell types of diseases of 415 interest and fell short of comprehensive discovery of disease-causing variants and genes. A unique 416 strength of our work is that it takes full advantage of the single-cell data to identify candidate risk 417 variants and genes. Our computational procedure leverages strong enrichment of genetic signals 418 in CM-specific OCRs to fine-map causal variants, greatly increasing the number of high confidence SNPs<sup>82</sup> (Fig. 4b). Our gene-mapping procedure effectively leverages fine-mapping 419 420 results and multiple sources of information linking SNPs to putative targets. This avoids the bias 421 of previous work that only considers one metric, e.g., distance, to link SNPs to genes, and increases 422 the sensitivity of detecting risk genes. As a result, we found high confidence genes (PIP  $\geq 0.8$ ) in 423 more than 1/3 of known AF-associated loci.

424 Our set of 45 candidate genes shed light on the genetics of AF. Earlier linkage studies implicated ion channels and structural proteins, as well as a few TFs<sup>86</sup>. Our results confirmed these earlier 425 426 findings and showed an even larger role of regulatory genes, including TFs and signaling proteins. In total, we identified 7 TFs with PIP  $\ge 0.8$  (Supplementary Table 7), and 18 at PIP  $\ge 0.5$ . These 427 428 included known AF genes, TBX5 (PIP 0.99), NKX2-5 (0.99), PITX2 (0.9), ZFHX3 (0.84) and 429 GATA4 (0.57), as well as TFs with roles in heart development such as HAND2 (0.87), ZEB2 (0.98), 430 and *PRRX1* (0.74). Our results also highlighted signal transduction pathways, including MAPK signaling<sup>75</sup>, Ephrin signaling<sup>76–78</sup> (Fig. 5h), G-protein coupled receptor signaling<sup>87</sup>, Wnt signaling<sup>88</sup> 431 (Supplementary Table 11) and FGF signaling<sup>61,62</sup> (*FGF9*, PIP = 0.94 and *FGF5* PIP = 0.53), all 432 433 previously implicated in heart development.

Despite the advances described above, our study has a few limitations. Our experimental data were limited to four anatomical locations of the ventricles, while some AF risk variants might act through atrial-specific CMs. However, it is worth noting that a recent study, using scRNA-seq based cellular atlas of the heart including all anatomic locations, found that AF candidate genes

were strongly enriched in ventricular CMs<sup>20</sup>. Additionally, our fine-mapping leveraged the almost
exclusive enrichment in CM-specific OCRs (Fig. 4a), and thus may miss variants acting on the AF
risk through other cell types. This possibility is suggested by a small number of candidate variants
showing accessibility specific to fibroblasts (Fig. 4g), known contributors to AF etiology<sup>89</sup>.
Finally, some disease variants potentially act transiently during development and might be missed
using adult heart samples.

444 Our investigation of tissue-sharing patterns of *cis*-eQTLs found that heart eQTLs located in 445 OCRs were dominated by those with likely broad effects across cell types (Fig. 6de). This result 446 may reflect the limited power of bulk eOTLs in detecting eOTLs acting on a low proportion of 447 cells, a finding supported by our power analysis. As additional support, studies using both sorted cell types<sup>90</sup> and single-cell technology<sup>91,92</sup> have shown that cell-type-specific eOTLs are common. 448 449 There are some caveats to our eQTL study. We interpreted the higher enrichment of heart eQTLs 450 in shared OCRs compared to cell-type specific OCRs (Fig. 6de) as the difference of detection 451 power. The assumption was that eQTLs from the two groups have similar effect sizes. However, 452 this assumption could be violated. Another caveat is that in our power analysis we assumed that 453 the variance of gene expression across samples is identical across cell types. This reflects the 454 limitation of our knowledge. Further work using single-cell RNA-seq or sorted cell populations 455 may better inform the power analysis.

In conclusion, by combining novel experimental and computational approaches, our study identified a number of risk variants and genes and revealed key insights of the genetics of AF. These data provide a rich resource for future functional studies. Importantly, our analytic framework, including the software for fine-mapping and risk gene identification, may provide a general model for the study of other complex phenotypes.

- 461
- 462
- 463
- 464
- 465
- 466
- 467 Methods
- 468

469 Data collection. Nuclei isolation from adult heart tissue. Heart tissue samples were obtained from 470 National Disease Research Interchange (NDRI) without identifying information. The work with 471 these samples was determined to be Non-Human subject research and approved by the IRB 472 committee of the University of Chicago (IRB19-1429). Samples were stored at -80°C and kept on 473 dry ice whenever outside of the freezer. We included samples from 4 regions (left and right 474 ventricles, interventricular septum, apex) from 3 male individuals (Supplementary Table 1). 475 Aliquots of each heart sample were prepared from frozen heart tissue using a tissue pulverizer, 476 which was cooled prior to pulverization for 20 minutes over dry ice. Aliquots assayed in this study 477 ranged from 86.7 mg to 141.6 mg. Prior to library preparation, we purified nuclei using 478 fluorescence-activated cell sorting (FACS) to remove debris and minimize contamination from 479 ambient RNA.

480 Single nuclei isolation was performed on the heart tissue aliquots as described in Litvinukova 481 et al. 2020<sup>20</sup>, with some modifications. Single heart aliquots were kept on dry ice until being 482 transferred into a precooled 2 mL dounce homogenizer (Sigma) with 2 mL homogenization buffer 483 (250 mM sucrose, 25 mM KCl, 5 mM MgCl2, 10 mM Tris-HCl, 1 mM dithiothreitol (DTT), 1x 484 protease inhibitor, 0.4 U/µl, RNaseIn, 0.2 U/µl SUPERaseIn, 0.1% Triton X-100 in nuclease-free 485 water). Samples were dounced 25 times with pestle A (loose) and 15 times with pestle B (tight), 486 filtered through a 40-µm cell strainer, and centrifuged (500g, 5 minutes, 4°C). Supernatant was 487 discarded and the nuclei pellet was suspended in nuclei resuspension buffer (1x PBS, 1% BSA, 488 0.2 U/µL RNaseIn) and stained with NucBlue Live ReadyProbes Reagents (ThermoFisher). 489 Hoechst-positive nuclei were enriched using fluorescence-activated cell sorting (FACS) on the 490 FACSAria (BD Biosciences), obtaining between 172,500 and 350,000 nuclei while targeting a 491 maximum of 350,000. Nuclei were sorted into 0.75 ml of resuspension buffer. Flow-sorted nuclei 492 were counted in a C-Chip Disposable Hemocytometer, Neubauer Improved (INCYTO) before 493 commencing with library preparation.

494

495 snRNA-seq library preparation and sequencing. A portion of the sorted nuclei suspension was 496 removed and brought to a concentration of between 700 and 1,200 nuclei per microliter. An 497 appropriate number of nuclei were loaded on the Chromium controller (10X genomics) in order to 498 target between 6,000-8,000 nuclei, according to V3 of the manufacturer's instructions for the 499 Chromium Next GEM Single Cell 3' Reagent Kits (10X Genomics)<sup>93</sup>. 3' gene expression libraries

were amplified with 15 cycles during sample index PCR. QC was performed on 3' gene expression
cDNA and final libraries using a Qubit Fluorometer (ThermoFisher) and an Agilent 2100
Bioanalyzer (Agilent). Libraries were sequenced on the NovaSeq 6000 (Illumina) or the NextSeq
500 (Illumina) at the University of Chicago's Genomics Facility using paired-end sequencing.

504

505 scATAC-seq library preparation and sequencing. scATAC-seq libraries were prepared according 506 to v1 of the manufacturer's guidelines for the Chromium Next GEM Single Cell ATAC Reagent 507 Kits (10X Genomics), with the modification that we started from nuclei that were isolated as 508 described above. Between 9,300 and 25,000 nuclei were tagmented using Transposition Mix (10X 509 Genomics) at 37°C for 1 h and loaded on the Chromium controller. We targeted between 6,000 510 and 10,000 nuclei for library preparation. QC was performed on final ATAC-seq libraries using a 511 Qubit Fluorometer and an Agilent 2100 Bioanalyzer. Libraries were sequenced on the 512 NovaSeq6000 or the NextSeq500 at the University of Chicago's Genomics Facility using paired-513 end sequencing.

514

515 Single-cell genomic data analysis. snRNA-seq pre-processing. FastQ files from 12 sequencing 516 experiments were individually processed using an in-house scRNA-seq pipeline dropRunner<sup>94</sup>. Briefly, dropRunner utilizes FastQC<sup>95,96</sup> to obtain guality control metrics followed by fast and 517 efficient alignment to human reference genome hg38 using STARsolo 2.6.197 in GeneFull mode 518 519 with other parameters set to default. STARsolo performs alignment and quantification of gene 520 expression in one package. We quantified expression at the gene level using Gencode v29 gene annotations<sup>98</sup> utilizing both intronic and exonic reads to improve clustering and downstream 521 522 analyses of the snRNA-seq data. We extracted the raw gene-by-barcode expression matrices output by STARsolo for downstream analyses. We used Seurat 3.2.199 in R 3.6.3 to analyze the snRNA-523 524 seq data. We combined all 12 expression matrices into a single Seurat object together with the 525 corresponding metadata such as donor and anatomical region. To filter low-quality nuclei, we removed barcodes that contained less than 1000 UMI. We also used DoubletFinder 2.0.3<sup>100</sup> with 526 527 pN = 0.015 and pK = 0.005 to account for doublets, which works by generating in-silico doublets 528 and performs clustering to identify nuclei that fall in the neighborhood of the generated doublets. 529 After quality control, we retained a total of 49,359 nuclei.

531 scATAC-seq pre-processing. FastQ files from 12 sequencing experiments were individually processed using 10x Genomics CellRanger-atac 1.2.0<sup>101</sup>. We used the command cellranger-atac 532 533 count to align the fastq files to human reference genome hg38, followed by marking and removing 534 duplicate reads, and producing a fragment file containing the mapped location of each unique 535 fragment in each nucleus. We used ArchR 0.9.5<sup>31</sup> to further pre-process the data and perform downstream analyses of the scATAC-seq data. Using ArchR, we converted the fragments file into 536 537 a tile matrix, which is a bin-by-barcode Tn5 insertion count matrix, using a bin-size of 500 bp. We 538 also generated a gene score count matrix using the "model 42" from ArchR, which aggregates Tn5 539 insertion signals from the entire gene body, scales signals with bi-directional exponential decays 540 from the TSS (extended upstream by 5 kb) and the transcription termination site, and accounts for 541 neighboring gene boundaries. Gene annotations were obtained from Gencode v29. To filter low 542 quality nuclei, we kept nuclei with at least 5,000 unique fragments and a TSS enrichment score of 6. We also used ArchR's doublet removal approach with default parameters, which is based on in-543 544 silico doublet generation. We removed nuclei with a doublet enrichment score greater than 1. After 545 quality control, we retained a total of 26,714 nuclei.

546

547 Cell-type identification from snRNA-seq and scATAC-seq. We performed normalization, 548 dimensionality reduction, and unsupervised clustering on snRNA-seq and scATAC-seq data in 549 order to identify cell-types. For snRNA-seq, we used Seurat's workflow which begins with 550 converting counts to log2 TP10k values using the NormalizeData function. Next, we found the top 551 2000 variable genes using FindVariableGenes and used these genes as input features for Principal 552 Component Analysis (PCA). We computed the top 30 principal components (PCs) for each cell 553 and used these for downstream analyses. We observed batch effects due to different donors, and 554 corrected this batch effect. This was done using the RunHarmony function from the Harmony  $1.0^{102}$  package with default parameters to regress out the donor variable from the PCs. Next, we 555 556 used the FindClusters in Seurat with a resolution of 0.2 on the harmony-corrected PCs to define 557 clusters. We also computed the corresponding UMAP to visualize the harmony-corrected PCs in 558 two dimensions. We used previously established cell-type markers in order to map clusters to cell types<sup>20,21</sup>. 559

560 We performed cell-type mapping for scATAC-seq using the ArchR package. We performed 561 dimensionality reduction on the tile matrix using the top 20,000 bins in terms of count across all

562 cells. We used the function addIterativeLSI with 2 iterations in order to perform latent semantic 563 indexing (LSI) on the scATAC-seq tile matrix and retained the top 50 LSI vectors. Similar to 564 snRNA-seq, we observed batch effects across different donors, and removed this effect using the 565 RunHarmony function. We used addClusters with resolution = 0.2 in order to cluster nuclei based on the harmony-corrected LSI vectors. addUMAP with min.dist = 0.4 was used to compute a 2-566 567 dimensional representation of the harmony-corrected LSI vectors. We visualized gene activity 568 scores, as defined in ArchR, using the same marker genes as in snRNA-seq to assign clusters to 569 cell-types.

570

571 **Defining and classifying open chromatin regions**. Insertion read counts were aggregated across 572 all cells in each cell-type to form a cell-type pseudo-bulk and peak calling was performed on 573 pseudo-bulk data of each cell-type. Using the function addReproduciblePeakSet in ArchR in 574 conjunction with MACS2<sup>103</sup>, a union set of 352,900 peaks were called in total across all cell-types 575 at FDR < 0.1. This set of peaks, called union set, were used for all downstream analyses.

576 In order to discover cell-type specific regulatory elements, a single-cell insertion count matrix 577 was created using the function addPeakMatrix in ArchR. Cells were grouped into their respective 578 cell-types and differential accessibility (DA) analysis was performed in a one-vs-all fashion, i.e., 579 one cell type vs. all other ones. To perform DA, we used getMarkerFeatures in ArchR with default 580 parameters, which uses the Wilcoxon rank-sum test on the log-normalized insertion count matrix. 581 To control for technical variation, cells from the cell-type group and the group of remaining cell 582 types are matched in terms of TSS enrichment and number of fragments. Using FDR < 10% and  $\log_2$  fold-change > 1, we found about 47% of the union set to be cell-type specific. 583

584 For OCRs that were not differentially accessible, we reasoned that these are more likely to be 585 shared. To further stratify these OCRs into different classes, based on sharing among different cell 586 types, we used a simple quantile-based method. First, we aggregated the ATAC-seq counts across 587 all cells within each cell-type for each non-DA peak and normalized the counts by the total sum 588 of counts in each cell-type. Next, we binarized the peaks within each cell-type based on whether 589 they are in the top 25% or not in terms of their normalized counts. In this way, we identify the top 590 25% accessible peaks in each cell-type. Finally, we count how many times a peak is 1, or highly 591 accessible, across cell-types. Through this strategy, we defined three disjoint sets: shared in 2-3 592 cell types, shared in 4+ cell types and the remaining peaks denoted as "non-DA". The last category

corresponds to peaks that are only highly accessible (top 25%) in one cell type but are not foundto be differentially accessible based on our criteria above.

595

596 Identifying putative TFs regulating chromatin accessibility. We used a set of 870 human motif 597 sequence instances from CisBP<sup>104</sup>. These motif annotations were added onto the ArchR object 598 using the addMotifAnnotations function. Next, enrichment analysis was performed for each motif 599 in each cell-type-specific set of peaks, using the peakAnnoEnrichment function in ArchR. The 600 function uses the hypergeometric test to assess the enrichment of the number of times a motif 601 overlaps with a given set of peaks, compared to random expectation. After correcting for multiple 602 testing within each cell-type, we used FDR < 1% to ascertain a set of motifs and their enrichment. 603 Motif enrichment analysis may find multiple TFs with similar motifs. To reduce the redundancy 604 and identify true TFs that drive gene regulation, we correlated the motif accessibility with gene 605 score activity of each TF, expecting that for true TFs, their expression levels should be positively 606 correlated with accessibility of their motifs across cells. We obtained motif accessibility scores 607 from chromVAR (using the addDeviationsMatrix function in ArchR) for each TF across all cells. 608 We obtained the corresponding TF gene activity scores using the "model 42" by ArchR (see 609 "scATAC-seq pre-processing"). These single-cell-level motif accessibility scores and gene scores, 610 however, are noisy given the sparsity of data at individual cells. We thus used a strategy similar to Cicero<sup>105</sup>, by aggregating cells into "metacells" based on similarity using a k-nearest neighbor 611 612 approach. Specifically, we found the k nearest neighbors to each cell using the LSI vectors of the 613 single-cell ATAC-seq data. We only retained sets of metacells that shared a maximum of 25% of 614 constituting cells. Metacells that shared more than 25% of cells were removed at random. Using k615 = 100, we created about 200 non-redundant meta-cells based on these criteria and averaged the 616 motif accessibility scores and gene scores across cells within each meta-cell. We then computed 617 Pearson's correlation between the gene scores and the motif accessibility scores across meta-cell. 618 We selected all TFs with a Pearson's correlation greater than 0.5.

619

Testing enrichment of GWAS risk variants in functional annotations. We obtained
 harmonized GWAS summary statistics for cardiovascular and some non-cardiovascular traits from
 the IEU OpenGWAS project. We removed SNPs with missing values, SNPs on non-autosomal

chromosomes, and indels. Utilizing approximately independent Linkage Disequilibrium (LD)
blocks generated by ldetect<sup>37</sup>, we assigned each SNP to one of 1700 LD blocks.

We used TORUS<sup>36</sup> to estimate the genome-wide enrichment of risk variants of GWAS traits in various functional annotations, including cell-type specific OCRs obtained from DA testing, and some generic annotations including coding, retrieved from UCSC Genome Browser database, and conserved sequences from Lindblad-Toh, K. *et al.* 2011<sup>106</sup>. We ran TORUS on each annotation, one at a time, to get the marginal enrichment reported in Fig. 4a. P-values for enrichment were estimated from the 95% confidence intervals returned by TORUS and were adjusted for multiple testing across all traits/cell-types using the Benjamini-Hochberg approach.

632

Fine-mapping causal variants in AF-associated loci. We used SuSiE<sup>107</sup> to perform functionally-633 634 informed fine-mapping. We used the susie rss function to fine-map each LD block, which takes 635 GWAS z-scores and an LD matrix for the SNPs in the block. Because only summary statistics 636 were available publicly, we used out-of-sample genotype information from 1000 Genome 637 Project<sup>108</sup> to construct LD matrices. We ran SuSiE with L = 1, which allows a single causal signal 638 for each LD block and is robust to mismatching LD patterns. We allow SNPs to have different 639 prior probabilities in fine-mapping. These prior probabilities were generated by TORUS using a 640 joint-model of the following annotations: CM specific ATAC, CM shared ATAC, non-CM ATAC, 641 UCSC conserved/coding. We fine-mapped a total of 122 LD blocks, each containing at least 1 642 SNP at genome-wide significance ( $P < 5 \ge 10^{-8}$ ).

643

Annotating putative AF causal variants with additional functional data. Fetal DHS and heart H3K27ac data were obtained from ENCODE. PC-HiC interactions were obtained from an earlier study conducted in iPSC derived CMs<sup>41</sup>. Only interactions found in at least 2 out of 3 replicates were included. Motif analysis was performed using R motifbreak package<sup>109</sup>. Only "strong" effects on motif scores, according to the package, were considered.

649

Assessing regulatory effects of candidate variants by Luciferase assay. Candidate regulatory elements were designed from CM-specific accessibility in hg38 and synthesized by IDT, with either the reference allele or SNP allele(s). Sequence was verified and then cloned into the pGL4.23 enhancer luciferase response vector with a minimal promoter. HL-1 cardiomyocytes

were co-transfected with luciferase response vector and a pRL control using Lipofectamine 3000,
cultured for 48 hr after transfection, then lysed and assayed using the Dual-Luciferase Reporter
Assay system (Promega).

657

658 Gene mapping procedure with Mapgen. We used the posterior inclusion probabilities (PIPs) 659 generated by SuSiE to calculate a gene-level PIP, reflecting the probability that a gene is a risk 660 gene. We assume there is a single causal gene per disease associated locus. Let  $Z_g$  be an indicator 661 variable describing whether gene g is causal ( $Z_g = 1$ ) or not ( $Z_g = 0$ ) for the trait. Assuming a single 662 causal SNP per locus, the probability that the gene is causal, which is denoted as "gene PIP", can 663 be then related to the probabilities of SNPs being causal variants:

 $P(Z_a = 1 | D) = \sum_i P(Z_a = 1 | \gamma_i = 1) P(\gamma_i = 1 | D),$ 

664

666

where  $\gamma_i$  is the indicator variable for whether SNP *i* is causal or not, and *D* is the GWAS summary 667 668 statistics. The term  $P(Z_g = 1 | \gamma_i = 1)$  is the probability that g is the causal gene if the causal SNP 669 is SNP *i*, and the term  $P(\gamma_i = 1|D)$  is simply the PIP of SNP *i*, or PIP<sub>i</sub>. So the gene PIP of a gene 670 is a weighted sum of PIPs of all SNPs, weighted by how much that gene is supported by each SNP 671 (see below). Since the PIPs of all SNPs in a block sum to 1, the gene PIP has an upper-bound of 672 1. In the rare cases where a gene spans two nearby blocks - e.g. when a gene has large introns, the 673 gene PIP may exceed 1, which can be interpreted as the expected number of causal variants 674 targeting the gene g.

To calculate the term  $P(Z_g = 1 | \gamma_i = 1)$ , we consider the location of the SNP *i* with relation to 675 676 the gene g, as well as functional genomic data linking SNP i with gene g. These data were used to 677 assign the weights, denoted as  $w_{ia}$ , between SNP *i* and gene *g*, reflecting how likely the SNP *i* 678 affects gene g. For example, if a SNP is inside an exon of a gene, then the SNP-gene will have weight 1. We note that  $w_{ig}$  and  $P(Z_g = 1 | \gamma_i = 1)$  have different semantics: it is possible that a 679 680 SNP affects multiple genes with weights all equal to 1, but there is only a single causal gene supported by any SNP. In other words, for a causal SNP *i*, the conditional probabilities  $P(Z_g =$ 681  $1|\gamma_i = 1$ ) should sum to 1 across all nearby genes g. So we need to normalize  $w_{ig}$  with: 682

683 
$$PP(Z_g = 1 | \gamma_i = 1) = \frac{w_{ig}}{\sum_g w_{ig}}$$

684

To assign the weight terms,  $w_{ig}$ , we follow these four steps capturing several scenarios where a 685 686 SNP may affect a gene: 1) If a SNP is in an exon or active promoter (promoter overlapping with OCR) of a gene, we assign the SNP to that gene with weight  $w_{ia} = 1.2$ ) If a SNP can be linked 687 688 to a gene's promoter via "enhancer loops", we assign the linked gene with weight  $w_{ia} = 1$ . Here, "enhancer loops" are defined based on Activity-By-Contact (ABC) scores (constructed from heart 689 ventricle data with ABC scores  $\geq 0.015$ )<sup>44</sup> and promoter-capture HiC data (from iPSC-CMs)<sup>41</sup>. 690 Considering the fact that Hi-C and PC-HiC may miss contacts between close regions due to 691 692 technical reasons, we also consider a SNP in OCR within 20 kb of an active promoter as an 693 "enhancer loop". 3) If a SNP is in a UTR but not in OCRs, suggesting that the SNP likely regulates 694 the containing gene through RNA processing mechanisms, e.g. RNA stability or alternative 695 polyadenylation, we will assign the SNP to the UTR-containing gene with weight  $w_{ia} = 1$ . 4) If a SNP is not linked to any gene via the criteria above, we use a distance-based weighting to assign 696 697 it to all genes within 1Mb. The weights follow an exponential decay function as below, where 698  $d_{iq}$  is the SNP-gene distance:

699

$$w_{ig} = e^{-d_{ig}/5 \times 10^4} \,.$$

The parameter of this weight function, 50 kb, was chosen based on the fact that most enhancers, estimated to be 84% using CRISPR deletion experiments<sup>110</sup>, are located within 100 kb of the target promoters. Using a weight of 50 kb here would lead to 87% of weights within 100 kb, with a simple area-under-curve calculation of the weight function above.

At any locus, having PIPs for all the genes in the locus allows us to define the "credible gene set" of the locus, much like the use of the term for SNPs<sup>107</sup>. Simply speaking, the credible set at the 80% level means the minimum set of genes in the locus whose sum of PIPs is greater than or equal to 80%. One complication is that some of the genes in the locus may span another nearby locus, as described above. In this case, while the final reported gene PIP is computed from both loci, we only use the PIP of the gene from the locus of interest to define the credible gene set of that locus.

711

Gene interaction network analysis. We used the STRING database (STRING)  $11.5^{111}$  to construct gene network. The analysis was done using Cytoscape  $3.8.2^{112}$ . The input genes are those at PIP >= 0.5 from our gene-mapping analysis. To create the gene network (Fig. 5h), we use all

default settings except that we use the recommended threshold for high-confidence interactions
(0.700) for interaction scores. Singletons, i.e., genes not having any interactions with other ones,
were not shown from the output network. We also used STRING to run functional enrichment
analysis based on sources including Gene Ontology<sup>113,114</sup>, Reactome Pathways<sup>115</sup> and KEGG<sup>116</sup>.

719

eQTL tissue sharing analysis. We started with the rationale of our eQTL tissue sharing analysis. For simplicity, consider eQTLs found in one tissue (heart in our case), and we study the sharing of these eQTLs in a second tissue. Let p denote the probability of eQTLs in the first tissue being shared in the second tissue. Assuming we have several functional categories of eQTLs, e.g. regulatory elements specific in a cell type, or shared across cell types, we can then break down pinto several categories with the simple relation:

$$p = \sum_{c} p_{c} w_{c}$$

$$D = \Delta_c P_c W_c$$
,

where *c* denotes a category,  $p_c$  is the probability of tissue sharing in eQTLs from category *c*, and  $w_c$  is the proportion of eQTLs in category *c*. We hypothesize that different eQTLs categories have distinct molecular mechanisms of modulating transcript levels, and thus different tissue sharing patterns. This simple analysis thus suggests that both  $w_c$  and  $p_c$  are important for our understanding of tissue sharing. For instance, some categories may have a highly tissue-specific pattern (low  $p_c$ ), but may constitute a small proportion of all eQTLs (low  $w_c$ ), thus these categories would have limited contribution to the overall level of tissue sharing among eQTLs.

734

Summary statistics of GTEx heart eQTLs. Summary statistics of eQTLs from the left ventricle were obtained from the GTEX v8 release<sup>14</sup>. We also obtained fine-mapping results using DAP-G<sup>38</sup>. The variants with posterior inclusion probability (PIP) greater than 0.8 were kept for downstream analyses. We refer to these putative causal variants as eQTLs henceforth. The total number of eQTL-gene pairs that passed the threshold is 1,216. Tissue sharing data on the same eQTLs were also obtained from GTEx<sup>14</sup>. These data provide information of whether these heart eQTLs are also associated with gene expression in the other tissues in GTEx.

742

743 *Defining functional categories of heart eQTLs.* eQTLs were intersected with genomic features. To 744 obtain a set of disjoint genomic features, we used a combination of the union peak set and generic 745 annotations. For generic annotations, the longest transcript was chosen for each gene body, and its

746 corresponding exons, UTRs, and introns were obtained for all protein coding genes. We partitioned 747 the union peak set into cell-type-specific categories based on the differential accessibility (DA) 748 analysis, as well as the shared categories defined using the quantile approach, as described earlier. 749 We note that DA analysis does not guarantee disjoint sets of features. Indeed, we find that cell 750 types such as lymphoid and myeloid share about 6% of their DA peaks, while CMs share at most 751 1% with the other cell-types. To make these cell-type DA sets disjoint, we moved any DA peaks 752 that occurred in multiple cell types from DA analysis, to the "Shared 2-3" and "Shared 4+" 753 categories (see "Defining and classifying OCRs") depending on the number of cell types in which 754 it occurred. A small percentage of peaks (< 1%) were affected by this step. The eQTLs in OCRs 755 that overlap with exons or UTRs, or eQTLs in non-DA OCRs, are ambiguous to assign, so they 756 were filtered from our analysis. The eQTLs in intronic OCRs were assigned based on the OCR 757 categories. Those eQTLs not intersecting with any functional category were designated in an 758 "unassigned" category.

759

*Estimating extent of tissue sharing in different categories of heart eQTLs.* GTEx has performed eQTL mapping jointly across all tissues. Using these results, we call a SNP an eQTL in a given tissue, if it passes the local false sign rate (LFSR) threshold of 1%. For any eQTL, we can thus determine the number of tissues where it is active.

764

765 Estimating eQTL enrichment in functional categories. All the fine-mapped heart eQTLs are 766 assigned to our set of categories. The proportion of eQTLs in each category is then compared with 767 the expected proportion by chance to obtain enrichment reported in Fig. 6d and 6e. We used 768 SNPsnap<sup>117</sup> to create a set of random control SNPs that match our eQTLs in LD and minor allele 769 frequency. The LD data is obtained from the European population genotypes from 1000 Genomes. 770 We generated 1000 random SNPs which is roughly how many high-confidence eQTLs were used. 771 The proportion of random SNPs in each category is then used as our estimated proportion by 772 chance.

773

# 774 Data availability

Our snRNA-seq and scATAC-seq data will be deposited to the Gene Expression Ombinus(GEO).

- 777
- 778 Code availability

- 779 Mapgen R package is available from https://github.com/xinhe-lab/Mapgen. Code for data
- 780 processing and analyses are available at https://github.com/xinhe-lab/heart\_atlas.
- 781
- 782
- 783

# 784 Acknowledgements:

- 785 This work was funded by National Institutes of Health (NIH) grants, R01MH110531
- and R01HG010773 (to X.H.), and R21 AI144417-02 (to O.B). This project has been made
- possible in part by grant number CZF2019-002431 from the Chan Zuckerberg Initiative DAF, an
- advised fund of Silicon Valley Community Foundation. We thank Xuanyao Liu for helpful
- 789 comments on the manuscript.
- 790

# 791 792 Main figures: 793

794



795

796 Fig. 1 | Overview of our experimental and computational framework. Left: SnRNA-seq and 797 scATAC-seq profiling to cluster cells and obtain open chromatin regions (OCRs) in each cell type. 798 Middle: Using OCRs and GWAS summary statistics to assess variant enrichment in cell-type-799 resolved OCRs. The enrichment results then provide prior for Bayesian statistical fine-mapping. 800 The resulting Posterior Inclusion Probabilities (PIPs) represent the probabilities of variants being 801 causal. The likely cell types through which the causal signals at each locus act can be identified by considering cell type information of likely causal variants. We may not always be able to identify 802 803 a single cell type per locus, so we assign probabilities to cell types. Right: Computational gene-804 mapping using PIPs from SNP fine-mapping and SNP-to-gene links to obtain gene level PIPs. 805 Note that the PIP of a SNP is partitioned into nearby genes in a weighted fashion, with more likely 806 target genes receiving higher weights (as indicated by thicker arrows). Prioritized genes can be 807 further assessed through external evidence such as gene networks and expression. 808



#### 810

Fig. 2 | Mapping cell types in the human heart. a, UMAP projection of individual cells from snRNA-seq and scATAC-seq colored by cell types. Stacked barplots on the right represent the proportions of cell-types from each of the three donors. b, Stacked track plots of chromatin accessibility at marker genes across cell types. The bottom part shows the gene track. c, Percent of nuclei expressing marker genes in each cell type. Colors represent log-normalized expression values.



818

819

820 Fig. 3 | Discovery of OCRs and transcriptional regulators in the human heart. a, Row-821 normalized accessibility of OCRs across all cell types. **b**, Number of cell-type-specific and shared 822 OCRs and their genomic distributions. c, Density plot of the  $log_{10}$  distance to nearest gene for all 823 cell-type-specific and shared OCRs. Colors of the lines for cell-type-specific OCRs follow the 824 same convention as in Figure 2a. Gray and black lines represent shared 2-3 and shared 4 OCRs. d, 825 Proportions of cell-type specific OCRs that overlap with DHS (upper panel). Bar graph (lower panel) shows the proportions of cell-type specific OCRs that overlap with H3K27ac regions (LV 826 827 = left ventricle, RV = right ventricle). Smooth muscle cells and neuronal cells are not shown due to the small numbers of peaks in these cell types. e, Enrichment of TF motifs in the OCRs specific 828 829 to each cell type. Shown are 76 TFs with FDR < 1% from motif enrichment analysis in at least one 830 cell-type, and correlation between motif enrichment and gene activity > 0.5. f, Gene scores (from 831 ArchR) and motif accessibility scores calculated with chromVar in OCRs for MEF2A (top) and 832 TBX5 (bottom) across all cells.

833

834

835



837

838 Fig. 4 | Statistical fine-mapping of loci associated with the AF risk. a, log<sub>2</sub> fold enrichment 839 (from the tool TORUS) of risk variants of various traits in cell-type-specific OCRs. **b**, Comparison of AF fine-mapping results under the informative prior using OCRs (Y-axis) vs. the results under 840 841 the uniform prior (X-axis). Each dot is a SNP, and color represents the annotation of SNPs. Dashed 842 line has a slope of 1. c, Summary of PIPs of variants. d, Summary of credible set sizes from fine-843 mapping of AF. e, Proportions of summed PIPs in disjoint functional annotation categories among 844 all the loci. f. Proportion of summed PIPs in disjoint functional annotation categories at each 845 individual locus. g, Proportion of summed PIPs into cell type-specific OCRs at each individual 846 locus, for loci with summed PIPs in OCR  $\geq 0.25$ . Highlighted are three loci with high proportions 847 in fibroblast, myeloid, lymphoid specific OCRs. h, Chromatin accessibility and additional 848 functional genomic annotations of 54 SNPs (PIP  $\geq 50\%$ ). i, Reporter activities in HL-1 cells of 849 regions containing selected SNPs, with both reference and alternative alleles. P-values were 850 calculated using a paired two-sided t-test.

851



854 Fig. 5 | Mapping putative risk genes of AF. a, Schematic demonstrating the calculation of gene-855 level PIPs. w<sub>s,g</sub> represents the weight of a gene (g) with respect to a SNP (S). If a SNP is in exon 856 or promoter of a gene, then the weight is 1 for that gene. If this is not the case, but the SNP can be 857 linked to a target gene via regulatory interactions, we also set weight as 1. If none of these 858 conditions apply, all nearby genes of a SNP receive distance-dependent weights. The weights are 859 then normalized so that the total weight of all genes for a given SNP is 1. See Methods for details. **b**, Manhattan plot of gene PIPs. Genes at PIP  $\geq 0.8$  at labeled. **c**, Summary of the sizes of 80% 860 861 credible gene sets from gene mapping. **d**, FGF9 locus: the top two tracks represent the  $-\log_{10} p$ value of SNPs from AF GWAS (with color representing LD) and their PIPs from SNP-level fine-862 863 mapping, respectively. Middle three tracks represent cell-type aggregated ATAC-seq signals (CM:

red, endothelial: green; fibroblast: purple), followed by heart H3K27ac and fetal DHS peak calls. The links represent interactions identified from promoter-capture HiC data in iPSC-derived CMs. The red links show interactions centered on the likely causal SNP. **e**, Log-normalized CM expression of genes at PIP >= 80% vs. other genes from the AF loci. **f**, Percentage of Mendelian disease genes from OMIM in each gene PIP bin. **g**, Top 5 Biological Processes (BP) and Molecular Functions (MF) GO terms from gene-set enrichment analysis of the 45 genes with PIP >= 80%. **h**, Gene interaction network of candidate AF genes (PIP >= 0.5) using STRING. Only genes with

interactions are shown. Interactions are defined using a confidence threshold of 0.7 by STRING.

872 Node sizes represent gene PIPs. Colors of genes indicate their shared molecular functions.



874

875 876

877 Fig. 6 | Tissue-sharing patterns of heart (LV) eOTLs from GTEx. a, Number of tissues where 878 LV-eQTLs are detected at local false sign rate (LFSR) < 1%. b, Violin plot showing the number 879 of tissues in which a specific eQTL is detected. Each row represents a different class of eQTLs, 880 assigned based on their overlap with OCRs categories and other genomic locations. Unassigned: 881 eQTLs that cannot be assigned to any functional class. c, Proportion of LV-eQTLs located in OCRs 882 of selected cell types (Cardiomyocytes, Endothelial cells, Fibroblast, and Immune cells) that were also detected as eQTLs in a second tissue. **d**, Proportion of LV-eQTLs (n = 1216) in each 883 884 functional class. For comparison, the proportions of random SNPs in all the classes are also shown. 885 The numbers near the bars represent the fold enrichment in heart eOTLs compared to random 886 SNPs. e. Enrichment of GTEx heart eOTLs in OCRs vary with the number of cell types where the OCRs are active. Lower panel shows the proportion of eOTLs (light blue) and control SNPs (dark 887 888 blue, chosen to match eQTLs in LD and MAF) overlapping OCRs. The OCRs are divided into 4 889 categories, based on the degree of sharing across cell types in heart: 1 = not shared, 4 = shared890 in  $\geq$ =4 cell types. The upper panel shows the enrichment of eOTLs in each OCR class compared 891 to expectation based on control SNPs.

893	Table 1   Top prioritized genes (gene PIP >= 0.95).
894	

Gene	Gene PIP	Supporting SNPs	SNP PIP	Link Method*	OMIM	CM- specific expressi on	Known AF risk gene	Reference
SYNPO2L	1.161	rs60632610	0.959	exon			$\checkmark$	[20215401, 33768119]
HCN4	1.108	rs7172038	0.959	ABC	$\checkmark$		$\checkmark$	[29987112]
ASAH1	1.061	rs7508	1	exon		$\checkmark$		[32015399]
ATXNI	1.000	rs73366713 rs113755256 rs73724866 rs7770062 rs59430691	0.267 0.205 0.187 0.158 0.157	PC-HiC PC-HiC PC-HiC PC-HiC PC-HiC				[21475249, 22306179]
EFNA5	1.000	rs6871532	0.288	distance		$\checkmark$		[23562676, 30909943, 25359705]
ERBB4	1.000	rs6738011	0.112	distance		$\checkmark$		[19632177]
KCNN2	1.000	rs337705 rs337708	0.477 0.119	distance distance			$\checkmark$	[19139040]
RPL3L	1.000	rs140185678	1	exon				[32870709, 32514796]
TUBA8	1.000	rs464901 rs361834	0.853 0.147	nearby OCR nearby OCR				[31398994]
EPHA3	0.999	rs35124509 rs6771054 rs2117137	0.375 0.154 0.108	exons distance distance				[17046737]
THRB	0.999	rs73041705 rs73032363 rs9841040 rs1865712	0.173 0.136 0.127 0.118	distance distance distance distance		~		[28740583]
ETVI	0.998	rs55734480 rs12154315 rs12112152	0.394 0.335 0.223	distance distance distance			~	[27775552, 29930145]
PITX2	0.997	rs2220427	0.193	distance			~	[28217939, 29367545, 32309338]

TBX5	0.997	rs7312625 rs883079 rs7955405 rs10507248	0.404 0.199 0.141 0.107	distance exon PC-HiC PC-HiC		$\checkmark$	$\checkmark$	[28057264]
CAMK2D	0.996	rs17446418 rs2285703	0.43 0.166	PC-HiC PC-HiC		>	$\checkmark$	[24030498]
PKP2	0.993	rs2045172	0.841	PC-HiC		$\checkmark$		[28740174]
NKX2-5	0.990	rs6882776 rs6891790 rs2277923 rs10071514	0.343 0.294 0.202 0.14	active promoter ABC/nearby OCR exon ABC/nearby OCR	>			[26805889]
LRIG1	0.982	rs34080181 rs900171	0.322 0.156	distance exon				[23558895, 19632177]
ZEB2	0.979	rs10496971	0.805	distance				[33398012]
TTN	0.977	rs3731746 rs2857265 rs3829748 rs3731748	0.317 0.265 0.182 0.15	exon exon exon exon	$\checkmark$	$\checkmark$	$\checkmark$	[30535219]
MYO18B	0.973	rs133902 rs133885	0.609 0.196	distance exon		$\checkmark$		[27858739]

895

896

897 \* In the Supporting SNPs column, only SNPs that contribute a fractional PIP (SNP PIP multiplied by the weight of

the SNP to that gene) of 0.1 or more are shown. *NR3C1* is not included because it does not have any SNPs with fractional PIP  $\ge 0.1$ .

900 \* Nearby OCR is defined as OCR within 20 kb of active promoter of the gene.

901

# 902 **References**

- 903 1. Benjamin, E. J. et al. Independent Risk Factors for Atrial Fibrillation in a Population-Based
- 904 Cohort: The Framingham Heart Study. *JAMA* **271**, 840–844 (1994).
- 905 2. Kornej, J., Börschel, C. S., Benjamin, E. J. & Schnabel, R. B. Epidemiology of Atrial
- 906 Fibrillation in the 21st Century. Circ. Res. 127, 4–20 (2020).
- 3. Roselli, C. *et al.* Multi-ethnic genome-wide association study for atrial fibrillation. *Nat. Genet.*50, 1225–1233 (2018).
- 909 4. Roselli, C., Rienstra, M. & Ellinor, P. T. Genetics of Atrial Fibrillation in 2020. Circ. Res.
- 910 **127**, 21–33 (2020).
- 911 5. Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
- 912 fibrillation biology. *Nat. Genet.* **50**, 1234–1239 (2018).
- 913 6. Arking, D. E. et al. Genetic association study of QT interval highlights role for calcium
- 914 signaling pathways in myocardial repolarization. *Nat. Genet.* **46**, 826–836 (2014).

915 7. Pfeufer, A. et al. Genome-wide association study of PR interval. *Nat. Genet.* 42, 153–159

- 8. Maurano, M. T. et al. Systematic Localization of Common Disease-Associated Variation in
- 918 Regulatory DNA. Science **337**, 1190–1195 (2012).
- 919 9. Pickrell, J. K. Joint analysis of functional genomic data and genome-wide association studies
- 920 of 18 human traits. Am. J. Hum. Genet. 94, 559–573 (2014).
- 921 10. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide
- 922 association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
- 11. Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. *Nature* 518, 317–
  330 (2015).
- 925 12. The ENCODE Project Consortium., Moore, J.E., Purcaro, M.J. et al. Expanded
- 926 encyclopaedias of DNA elements in the human and mouse genomes. *Nature* 583, 699–710927 (2020).
- 928 13. Nicolae, D. L. et al. Trait-associated SNPs are more likely to be eQTLs: annotation to
- 929 enhance discovery from GWAS. *PLoS Genet.* 6, e1000888 (2010).
- 930 14. The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
- 931 human tissues. *Science* **369**, 1318–1330 (2020).
- 15. The GTEx Consortium.. Genetic effects on gene expression across human tissues. *Nature*550, 204–213 (2017).
- 934 16. Urbut, S. M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for
- estimating and testing effects in genomic studies with multiple conditions. *Nat. Genet.* 51, 187–
  195 (2019).
- 17. Thurman, R. E. et al. The accessible chromatin landscape of the human genome. *Nature* 489,
  75–82 (2012).
- 18. Yao, D. W., O'Connor, L. J., Price, A. L. & Gusev, A. Quantifying genetic effects on disease
  mediated by assayed gene expression levels. *Nat. Genet.* 52, 626–633 (2020).
- 941 19. Habib, N. et al. Massively-parallel single nucleus RNA-seq with DroNc-seq. Nat. Methods
- 942 14, 955–958 (2017).
- 943 20. Litviňuková, M. *et al. Cells* of the adult human heart. *Nature* **588**, 466–472 (2020).
- 944 21. Tucker, N. R. *et al.* Transcriptional and Cellular Diversity of the Human Heart. *Circulation*
- 945 **142**, 466–482 (2020).
- 946 22. Buenrostro, J. D. et al. Single-cell chromatin accessibility reveals principles of regulatory
- 947 variation. *Nature* **523**, 486–490 (2015).
- 948 23. Cusanovich, D. A. et al. Multiplex single cell profiling of chromatin accessibility by
- 949 combinatorial cellular indexing. *Science* **348**, 910–914 (2015).
- 950 24. Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal
- variants by statistical fine-mapping. *Nat. Rev. Genet.* **19**, 491–504 (2018).
- 952 25. Wen, X., Lee, Y., Luca, F. & Pique-Regi, R. Efficient Integrative Multi-SNP Association
- 953 Analysis via Deterministic Approximation of Posteriors. Am. J. Hum. Genet. 98, 1114–1129
- 954 (2016).

<sup>916 (2010).</sup> 

- 955 26. Weissbrod, O. et al. Functionally informed fine-mapping and polygenic localization of
- 956 complex trait heritability. *Nat. Genet.* **52**, 1355–1363 (2020).
- 957 27. Segrè, A. V. et al. Common Inherited Variation in Mitochondrial Genes Is Not Enriched for
- Associations with Type 2 Diabetes or Related Glycemic Traits. *PLoS Genetics* **6**, e1001058
- 959 (2010).
- 960 28. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set
- analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
- 962 29. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-
- 963 density imputation and islet-specific epigenome maps. *Nat. Genet.* **50**, 1505–1513 (2018).
- 964 30. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
- transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* 36,
  411–420 (2018).
- 967 31. Granja, J. M. *et al.* ArchR is a scalable software package for integrative single-cell chromatin
  968 accessibility analysis. *Nat. Genet.* 53, 403–411 (2021).
- 32. Thurman, R. E. *et al.* The accessible chromatin landscape of the human genome. *Nature* 489,
  75–82 (2012).
- 971 33. Buenrostro, J. D. et al. Integrated Single-Cell Analysis Maps the Continuous Regulatory
- 972 Landscape of Human Hematopoietic Differentiation. Cell 173, 1535-1548.e16 (2018).
- 973 34. Schep, A. N., Wu, B., Buenrostro, J. D. & Greenleaf, W. J. chromVAR: inferring
- transcription-factor-associated accessibility from single-cell epigenomic data. *Nat. Methods* 528,
  142 (2017).
- 976 35. Olson, E. N. Gene regulatory networks in the evolution and development of the heart.
- 977 *Science* **313**, 1922–7 (2006).
- 978 36. Wen, X. Molecular QTL discovery incorporating genomic annotations using Bayesian false
- 979 discovery rate control. Ann. Appl. Statistics 10, 1619–1638 (2016).
- 980 **37**. Berisa, T. & Pickrell, J. K. Approximately independent linkage disequilibrium blocks in
- human populations. *Bioinformatics* **32**, 283–285 (2016).
- 982 38. Wen, X., Lee, Y., Luca, F. & Pique-Regi, R. Efficient Integrative Multi-SNP Association
- Analysis via Deterministic Approximation of Posteriors. *Am. J. Hum. Genet.* **98**, 1114–1129
- 984 (2016).
- 985 39. Morgan, B. *et al.* Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros
- to regulate lymphocyte differentiation. *EMBO J.* **16**, 2004–2013 (1997).
- 987 40. Baert, L., Ahmed, M. C., Manfroi, B. & Huard, B. The number 13 of the family: a
- 988 proliferation inducing ligand. Curr. Opin. Immunol. 71, 132–137 (2021).
- 989 41. Montefiori, L. E. et al. A promoter interaction map for cardiovascular disease genetics. Elife
- 990 **7**, e35788 (2018).
- 42. Kapoor, A. et al. Multiple SCN5A variant enhancers modulate its cardiac gene expression
- 992 and the QT interval. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 201808734 (2019).
- 993 43. Claycomb, W. C. et al. HL-1 cells: A cardiac muscle cell line that contracts and retains
- 994 phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U.S.A. 95, 2979-

- 995 2984 (1998).
- 44. Nasser, J. et al. Genome-wide enhancer maps link risk variants to disease genes. *Nature* 593,
  238–243 (2021).
- 45. DiFrancesco, D. HCN4, Sinus Bradycardia and Atrial Fibrillation. *Arrhythmia Electrophysiol Rev.* 4, 9 (2015).
- 1000 46. Ouwerkerk, A. F. van *et al.* Identification of Functional Variant Enhancers Associated With
- 1001 Atrial Fibrillation. Circ. Res. 127, 229–243 (2020).
- 1002 47. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- 1003 Association Studies Using Summary Statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 48. Claussnitzer, M. *et al.* A brief history of human disease genetics. *Nature* 577, 179–189
  (2020).
- 1006 49. Ouwerkerk, A. F. van *et al.* Epigenetic and Transcriptional Networks Underlying Atrial
- 1007 Fibrillation. Circ. Res. 127, 34–50 (2020).
- 1008 50. Nadadur, R. D. et al. Pitx2 modulates a Tbx5 -dependent gene regulatory network to
- 1009 maintain atrial rhythm. Sci. Transl. Med. 8, 354ra115 (2016).
- 1010 51. Drabkin, M. et al. Nocturnal Atrial Fibrillation Caused by Mutation in KCND2, Encoding
- 1011 Pore-Forming (α) Subunit of the Cardiac Kv4.2 Potassium Channel. *Circulation Genom. Precis.*
- 1012 *Medicine* **11**, e002293 (2018).
- 1013 52. Mahida, S. et al. Overexpression of KCNN3 results in sudden cardiac death. *Cardiovasc*.
- 1014 *Res.* **101**, 326–334 (2013).
- 1015 53. Purohit, A. et al. Oxidized Ca2+/Calmodulin-Dependent Protein Kinase II Triggers Atrial
- 1016 Fibrillation. Circulation 128, 1748–1757 (2013).
- 1017 54. Yin, H. et al. TAB2 deficiency induces dilated cardiomyopathy by promoting RIPK1-
- 1018 dependent apoptosis and necroptosis. J. Clin. Invest. (2022) doi:10.1172/jci152297.
- 1019 55. Laforest, B. *et al.* Atrial fibrillation risk loci interact to modulate Ca2+-dependent atrial
- 1020 rhythm homeostasis. J Clin Invest **129**, 4937–4950 (2019).
- 56. Dai, W. *et al.* A calcium transport mechanism for atrial fibrillation in Tbx5-mutant mice. *Elife* 8, e41814 (2019).
- 1023 57. Sahoo, S. K. & Kim, D. H. Characterization of calumenin in mouse heart. *BMB Rep.* 43,
  1024 158–63 (2010).
- 1025 58. Yamaguchi, N. et al. Cardiac Pressure Overload Decreases ETV1 Expression in the Left
- 1026 Atrium, Contributing to Atrial Electrical and Structural Remodeling. *Circulation* 143, 805–820
- 1027 (2021).
- 1028 59. Rommel, C. *et al.* The Transcription Factor ETV1 Induces Atrial Remodeling and
- 1029 Arrhythmia. Circ. Res. 123, 550–563 (2018).
- 1030 60. Shekhar, A. *et al.* Transcription factor ETV1 is essential for rapid conduction in the heart. J.
- 1031 *Clin. Invest.* **126**, 4444–4459 (2016).
- 1032 61. Huang, J. et al. Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of
- 1033 C2C12 and human muscle cells. *Cell Cycle* **18**, 1–19 (2019).
- 1034 62. Itoh, N. & Ohta, H. Pathophysiological roles of FGF signaling in the heart. Front. Physiol. 4,

- 1035 247 (2013).
- 1036 63. Hsu, J. et al. Genetic Control of Left Atrial Gene Expression Yields Insights into the Genetic
- 1037 Susceptibility for Atrial Fibrillation. *Circulation Genom. Precis. Medicine* **11**, e002107 (2018).
- 1038 64. Tsai, C.-T. et al. Next-generation sequencing of nine atrial fibrillation candidate genes
- 1039 identified novel de novo mutations in patients with extreme trait of atrial fibrillation. J. Med.
- 1040 Genet. **52**, 28 (2015).
- 1041 65. Scott, J. D. & Santana, L. F. A-Kinase Anchoring Proteins. *Circulation* **121**, 1264–1271
- 1042 (2010).
- 1043 66. Huang, T. *et al.* AKAP5 anchors PKA to enhance regulation of the HERG channel. *Int. J.*1044 *Biochem. Cell Biology* 122, 105741 (2020).
- 1045 67. Nasser, J., Bergman, D.T., Fulco, C.P. *et al.* Genome-wide enhancer maps link risk variants 1046 to disease genes. *Nature* **593**, 238–243 (2021).
- 1047 68. Ahlberg, G. et al. Rare truncating variants in the sarcomeric protein titin associate with
- 1048 familial and early-onset atrial fibrillation. *Nat. Commun.* 9, 4316 (2018).
- 1049 69. Choi, S. H. et al. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk. Circ.
- 1050 Res. 126, 200–209 (2020).
- 1051 70. Ouwerkerk, A. F. van *et al.* Identification of atrial fibrillation associated genes and functional
  1052 non-coding variants. *Nat. Commun.* 10, 4755 (2019).
- 1053 71. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased
- 1054 coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids* 1055 *Res.* 47, gky1131 (2018).
- 1056 72. Benaglio, P. et al. Allele-specific NKX2-5 binding underlies multiple genetic associations
- 1057 with human electrocardiographic traits. *Nat. Genet.* **51**, 1506–1517 (2019).
- 1058 73. Schindler, Y. L. et al. Hand2 elevates cardiomyocyte production during zebrafish heart
- 1059 development and regeneration. *Development* 141, 3112–3122 (2014).
- 1060 74. Cohen, A. S. A. et al. Haploinsufficiency of the basic helix-loop-helix transcription factor
- 1061 HAND2 causes congenital heart defects. Am. J. Med. Genet. 182, 1263–1267 (2020).
- 1062 75. Romero-Becerra, R., Santamans, A. M., Folgueira, C. & Sabio, G. p38 MAPK Pathway in
- 1063 the Heart: New Insights in Health and Disease. Int. J. Mol. Sci. 21, 7412 (2020).
- 1064 76. O'Neal, W. T. *et al.* Ephrin–Eph signaling as a potential therapeutic target for the treatment 1065 of myocardial infarction. *Med. Hypotheses* **80**, 738–744 (2013).
- 1066 77. Su, S. *et al.* Essential roles of EphrinB2 in mammalian heart: from development to diseases.
- 1067 *Cell Commun. Signal.* **17**, 29 (2019).
- 1068 78. Chen, K. et al. EphB4 Forward-Signaling Regulates Cardiac Progenitor Development in
- 1069 Mouse ES Cells. J. Cell Biochem. 116, 467–475 (2015).
- 1070 79. Chun, S. *et al.* Limited statistical evidence for shared genetic effects of eQTLs and
- 1071 autoimmune disease-associated loci in three major immune cell types. *Nat. Genet.* **49**, 600–605 (2017).
- 1073 80. Degner, J. F. et al. DNaseI sensitivity QTLs are a major determinant of human expression
- 1074 variation. *Nature* **48**2, 390–394 (2012).

- 1075 81. Wijst, M. G. P. van der et al. Single-cell RNA sequencing identifies celltype-specific cis-
- 1076 eQTLs and co-expression QTLs. *Nat. Genet.* **50**, 493–497 (2018).
- 1077 82. Hocker, J. D. *et al.* Cardiac cell type–specific gene regulatory programs and disease risk
  1078 association. *Sci. Adv.* 7, eabf1444 (2021).
- 1079 83. Chiou, J. *et al.* Single-cell chromatin accessibility identifies pancreatic islet cell type– and
- 1080 state-specific regulatory programs of diabetes risk. *Nat. Genet.* **53**, 455–466 (2021).
- 1081 84. Chiou, J. *et al.* Interpreting type 1 diabetes risk with genetics and single-cell epigenomics.
- 1082 Nature **594**, 398–402 (2021).
- 1083 85. Corces, M. R. et al. Single-cell epigenomic analyses implicate candidate causal variants at
- 1084 inherited risk loci for Alzheimer's and Parkinson's diseases. *Nat. Genet.* **52**, 1158–1168 (2020).
- 1085 86. Lozano-Velasco, E., Franco, D., Aranega, A. & Daimi, H. Genetics and Epigenetics of Atrial
- 1086 Fibrillation. Int. J. Mol. Sci. 21, 5717 (2020).
- 1087 87. Wang, J., Gareri, C. & Rockman, H. A. G-Protein–Coupled Receptors in Heart Disease.
- 1088 Circ. Res. 123, 716–735 (2018).
- 1089 88. Foulquier, S. et al. WNT Signaling in Cardiac and Vascular Disease. Pharmacol. Rev. 70,
- 1090 68–141 (2018).
- 1091 89. Nattel, S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. *JACC*
- 1092 *Clin. Electrophysiol.* **3**, 425–435 (2017).
- 1093 90. Schmiedel, B. J. et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene
- 1094 Expression. *Cell* **175**, 1701-1715.e16 (2018).
- 1095 91. Study, L. C. et al. Single-cell RNA sequencing identifies celltype-specific cis-eQTLs and co-
- 1096 expression QTLs. Nat. Genet. 50, 493–497 (2018).
- 1097 92. Wijst, M. G. van der et al. The single-cell eQTLGen consortium. Elife 9, e52155 (2020).
- 1098 93. Chromium Single Cell 3' Reagent Kits User Guide (v3.1 Chemistry).
- 1099 https://support.10xgenomics.com/single-cell-gene-expression/library-prep/doc/user-guide-
- 1100 chromium-single-cell-3-reagent-kits-user-guide-v31-chemistry (2019).
- 1101 94. Selewa, A. et al. Systematic Comparison of High-throughput Single-Cell and Single-Nucleus
- 1102 Transcriptomes during Cardiomyocyte Differentiation. *Sci. Rep.* **10**, 1535 (2020).
- 1103 95. FastQC. https://qubeshub.org/resources/fastqc (2015).
- 1104 96. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online].
- 1105 http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2010).
- 1106 97. Kaminow, B., Yunusov, D. & Dobin, A. STARsolo: accurate, fast and versatile
- 1107 mapping/quantification of single-cell and single-nucleus RNA-seq data. *Biorxiv*
- 1108 2021.05.05.442755 (2021) doi:10.1101/2021.05.05.442755.
- 1109 98. Frankish, A. *et al.* GENCODE reference annotation for the human and mouse genomes.
- 1110 Nucleic Acids Res. 47, gky955- (2018).
- 1111 99. Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902.e21
- 1112 (2019).
- 1113 100. McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet Detection in
- 1114 Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 8, 329-337.e4

- 1115 (2019).
- 1116 101. Satpathy, A. T. et al. Massively parallel single-cell chromatin landscapes of human immune
- 1117 cell development and intratumoral T cell exhaustion. *Nat. Biotechnol.* **37**, 925–936 (2019).
- 1118 102. Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with
- 1119 Harmony. Nat. Methods 16, 1289–1296 (2019).
- 1120 103. Zhang, Y. et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol. 9, R137–R137
- 1121 (2008).
- 1122 104. Weirauch, M. T. *et al.* Determination and Inference of Eukaryotic Transcription Factor
- 1123 Sequence Specificity. *Cell* **158**, 1431–1443 (2014).
- 1124 105. Pliner, H. A. *et al.* Cicero Predicts cis-Regulatory DNA Interactions from Single-Cell
- 1125 Chromatin Accessibility Data. Mol. Cell. 71, 858-871.e8 (2018).
- 1126 106. Lindblad-Toh, K. et al. A high-resolution map of human evolutionary constraint using 29
- 1127 mammals. *Nature* **478**, 476–82 (2011).
- 1128 107. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
- selection in regression, with application to genetic fine mapping. J. R. Stat. Soc. Ser. B.
- 1130 Statistical Methodol. 82, 1273–1300 (2020).
- 1131 108. Clarke, L. et al. The international Genome sample resource (IGSR): A worldwide collection
- 1132 of genome variation incorporating the 1000 Genomes Project data. *Nucleic Acids Res.* **45**, D854– 1133 D859 (2017).
- 1134 109. Coetzee, S. G., Coetzee, G. A. & Hazelett, D. J. motifbreakR: an R/Bioconductor package
- 1135 for predicting variant effects at transcription factor binding sites. *Bioinformatics* **31**, 3847–3849
- 1136 (2015).
- 1137 110. Fulco, C. P. et al. Activity-by-contact model of enhancer-promoter regulation from
- 1138 thousands of CRISPR perturbations. *Nat. Genet.* **51**, 1664–1669 (2019).
- 1139 111. Szklarczyk, D. et al. The STRING database in 2021: customizable protein-protein
- 1140 networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic*
- 1141 Acids Res. 49, gkaa1074- (2020).
- 1142 112. Shannon, P. et al. Cytoscape: A Software Environment for Integrated Models of
- 1143 Biomolecular Interaction Networks. *Genome Res.* **13**, 2498–2504 (2003).
- 1144 113. Ashburner, M. *et al.* Gene Ontology: tool for the unification of biology. *Nat. Genet.* 25, 25–
  1145 29 (2000).
- 1146 114. The Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine.
- 1147 Nucleic Acids Res. 49, D325–D334 (2020).
- 1148 115. Jassal, B. et al. The reactome pathway knowledgebase. *Nucleic Acids Res.* 48, D498–D5031149 (2019).
- 1150 116. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic*
- 1151 Acids Res. 28, 27–30 (2000).
- 1152 117. Pers, T. H., Timshel, P. & Hirschhorn, J. N. SNPsnap: a Web-based tool for identification
- and annotation of matched SNPs. *Bioinformatics* **31**, 418–420 (2015).